|
Current tools used for the clinical diagnosis of OIPN
|
National Cancer Institute-Common Toxicity Criteria (NCI-CTC)
|
[23]
|
|
Total Neuropathy Score clinical version (TNSc)
|
[24]
|
|
Modified Inflammatory Neuropathy Cause and Treatment (INCAT) group sensory sum score (mISS)
|
[25]
|
|
European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30
|
[27]
|
|
CIPN (chemotherapy induced peripheral neuropathy) 20 quality-of-life measures
|
[26]
|
|
Skin biopsy and quantified intraepidermal nerve fiber density
|
[28, 29]
|
|
LDI technology
|
[22]
|
|
Surface electromyography recording
|
[30]
|
|
Comments for the ideal CIPN assessment tools
|
Specific to CIPN; validated in different types of chemotherapy; easy for patients to understand and complete; can be used in postal questionnaires as well as face to face; performs consistently in different settings; requires minimal training in use and scoring; sensitive to change; detects CIPN early; and reliable with minimal interrater variability
|
[2]
|
